Familial hypercholesterolemia (FH) is an inherited disorder characterized by high plasma LDL-C (low-density lipoproteincholesterol) levels. The vast majority of FH patients carry a mutation in the coding region of LDLR, APOB, or PCSK9. We set out to identify the culprit genetic defect in a large family with clinical FH, in whom no mutations were identified in the coding regions of these FH genes.
F amilial hypercholesterolemia (FH), a common inherited dominant disorder with a prevalence of 1:250, is characterized by high plasma levels of LDL-C (low-density lipoprotein-cholesterol). 1 Lifelong exposure to elevated LDL-C levels leads to an increased risk for cardiovascular disease, with an estimated odds ratio of 2.2 to 25.8. 2, 3 Patients are diagnosed with FH based on clinical criteria and subsequent genetic analysis is confirmative in a large proportion of FH patients. The Dutch Lipid Network Criteria, which encompasses data about family and medical history, the presence of tendon xanthoma, corneal arcus, and LDL-C levels are widely used in clinic. For molecular confirmation the genes encoding low-density lipoprotein receptor (LDLR, FH1), apolipoprotein B (APOB, FH2), or proprotein convertase subtilisin/kexin type 9 (PCSK9, FH3) are analyzed for the presence of pathogenic mutations. However, no mutations are found in the coding regions of these genes in ≈5% to 10% of the patients with a high clinical FH score, 4 and these are commonly referred to as FH4.
Variants in the noncoding region of the LDLR gene have been found in a small number of FH patients. 5 These variants result in either absent or decreased levels of the LDLR protein by virtue of their effect on splicing of LDLR mRNA. Adequate splicing of mRNA is dependent on the recognition of the exon-intron boundaries by the spliceosome 6 and involves recognition of particular signal sequences of nucleotides in pre-mRNA. Mutations in the signal sequences can abolish or weaken splice sites, or activate cryptic splice sites. Depending on the position of the variant, this can lead to either abnormal or alternative splicing of the pre-mRNA that might lead to abolished or altered and often nonfunctional proteins. Most aberrant spliced transcripts enter the nonsense-mediated mRNA decay pathway, resulting in elimination of the transcript. 7 The clinical relevance of deep intronic variants in FH is widely unknown. Here we report a novel deep intronic variant in LDLR that leads to abnormal splicing and cosegregates with high LDL-C. Furthermore, we analyzed the prevalence and clinical consequence of this newly identified variant in a large cohort of patients, referred for genetic FH analysis. This novel variant was identified in 3 of 1 245 FH4 patients, underscoring the need for whole LDLR gene sequencing, including introns, in FH4 patients.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure, since privacy legislation does not allow sharing genetic and clinical data of the participants in this study. The study was approved by the Institutional Review Board at the Academic Medical Center in Amsterdam, and all subjects gave written informed consent before participation in this study. Detailed methods are available in the Data Supplement.
RESULTS
Whole genome sequencing of DNA derived from 9 subjects from family 1 retrieved 190 rare (exonic and intronic) variants, which were present in the affected, but not in the unaffected family members (Table I in the Data Supplement). Manual exploration of these 190 variants identified a rare heterozygous single base pair substitution in intron 14 of LDLR (c.2140+103G>T, Chr19(GRCh37):g.11231301G>T) which was present in all family members with the FH phenotype, but not in the unaffected family members (Figure 1; family 1 ). This variant was of special interest since it was present in one of the major FH causing genes (ie, LDLR). TaqMan analysis of the DNA of one additional affected family member, who was not included in the original whole genome sequencing analysis (ID 20), confirmed the presence of the newly identified rare variant in LDLR.
In silico analysis with 5 splicing prediction algorithms predicted an increase in splicing signal at a potential cryptic splice donor site consensus, 5 base pairs (bp) before the identified variant ( Table 1) . Activation of this cryptic splice site during transcription would in theory result in a 97 bp intronic DNA insertion and a premature stop in exon 15 of LDLR, as is shown in Figure 2 .
To assess the in vivo effect of the variant, cDNA polymerase chain reaction products were generated from RNA of the proband of family 1. A band of 409 bp was identified in addition to the wild-type LDLR cDNA of 312 bp ( Figure 3) . Sequencing of the 409 bp band confirmed the 97 bp intron insertion between exon 14 and 15, as predicted with the in silico analysis.
Two cohorts of FH patients were examined for the presence of the c.2140+103G>T variant. In the nextgeneration sequencing FH cohort, comprising 2 145 patients, we identified 5 heterozygous carriers (from 4 families) of the c.2140+103G>T variant, which translates in a prevalence of 0.23% (5/2154). The 5 patients did not carry any mutation in LDLR, APOB, or PCSK9. In the FH4 cohort, consisting of 1 245 FH patients negative for pathogenic mutations in LDLR, APOB, and PCSK9 who had a mean (±SD) LDL-C of 230.3±76.1 mg/dL (Table 2) , 3 additional unrelated carriers of the novel variant were identified, which does result in a similar prevalence of 0.24% (3/1245) as the first FH cohort. Taken together, a total of 8 additional variant carriers (from 7 unrelated families) were identified.
We collected plasma and DNA from family members of one of the 8 newly identified carriers to examine the segregation of c.2140+103G>T with the FH phenotype in a second family. This family, family 2, also showed 100% penetrance of this variant with the FH phenotype ( Figure 1, family 2) . While combining the data of family 1 and 2, we observed that the mean LDL-C in carriers of the c.2140+103G>T variant was 252.8±64.5 mg/dL after correction for use of lipidlowering therapies (Table 3) , which is above the 99th percentile for age and sex, and significantly (P<0.001) higher than the mean LDL-C of 120.7±35.9 mg/dL in noncarriers in these families. Only the index patient from family 1 had a history of cardiovascular disease (myocardial infarction).
DISCUSSION
We identified the deepest intronic variant in intron 14 of LDLR, c.2140+103G>T known to date, in patients with an FH phenotype. This variant fully segregated with the high LDL-C phenotype in 2 families. In addition, 8 individuals from 7 different families were found to be heterozygous carriers of this mutation, with a prevalence of 0.24% in 2 independent FH cohorts. The c.2140+103G>T variant causes a cryptic splice site in LDLR, resulting in a 97 bp intron retention between exon 14 and exon 15, which leads to a frameshift and a premature stop codon in exon 15. This deep intronic mutation likely results in a truncated LDLR protein missing the transmembrane and cytosolic domain. Alternatively, the generated mRNA enters the nonsense-mediated mRNA decay pathway resulting in a smaller amount of newly synthesized LDLR protein. 7, 10 Considering the visibility of cDNA containing the intron retention in the electrophoresis gel in Figure 2 , one could speculate that the natural splice site in the affected allele is substantially abolished.
Mutations in the introns of LDLR resulting in an FH phenotype have been described before. These intronic variants are mostly located within 20 bp of the exonintron boundary, and an extensive cosegregation analysis of the mutation is usually not performed. 5 The variant in our study, however, was identified 103 nucleotides downstream from the intron-exon boundary of exon and intron 14, which is deeper in the intronic region than many of the studies ever described. Moreover, we performed cosegregation analysis, which confirmed the association with high LDL-C phenotype, as we found a 100% penetrance. Lastly, our large cohort of FH patients allowed us to assess the prevalence of this variant. Although the latter was found to be relatively low (prevalence of 0.23%-0.24%), we deem the results of the current study to be relevant, as it clearly shows that an exonic centered analysis of genomic data may result in ommitance of functional defects in patients with FH. As a matter of fact; 8 patients who were screened for a molecular cause of their clinical FH in our 2 FH cohorts, were considered not to be carrier of a causative mutation. The more elaborate analysis focusing on this deep intronic variant, now teaches us that our initial diagnosis was incorrect. This has a clinical consequence, as this genetic diagnosis forms the basis for further pedigree analysis in many screening programs. We therefore advocate to additionally focus on potential splice site defects in FH patients, in whom no exonic variant is found in the initial molecular screening.
Our data are a confirmation of the relevance of other studies focusing on intronic variants in FH. In their study, Kulseth et al 11 found a carrier of a deep intronic variant in intron 14, c.2140+86C>G, in LDLR. The latter variant was found in 1 patient through extensive mRNA analysis of 30 FH patients with multiple primer combinations covering the whole transcript of LDLR. Our current study shows that also deeper intronic vari- cDNA PCR products of the proband of family 1 (patient) and a healthy control were run on a 1% agarose gel. PCR products were produced using primers covering the boundary between exon 14 and 15. The patient shows an additional PCR product of ≈400 base pairs (bp) length, while the control only shows the expected PCR product.
ants in LDLR can cause FH and that the variant was not restricted to 1 family.
Interestingly, recently another intronic variant in intron 14, c.2140+5G>A, with a minor allele frequency of 2.2%, was associated with a reduction in non-HDL-C (high-density lipoprotein-cholesterol) in a genome-wide association study among >100 000 Icelanders. 12 In silico analysis predicted an intronic insertion and a premature stop at approximately the same position as our novel variant, which, in theory, would result in a similar truncated and thus dysfunctional LDLR protein and hence high LDL-C. This is in contrast to the reduced non-HDL-C found for c.2140+5G>A. While we confirmed the insertion of our variant, the in silico predicted effects of c.2140+5G>A on insertion and splicing were not confirmed, so its definite effect on the LDLR mRNA remains unclear. It might be, that the in silico prediction of this variant is not in accordance with the observed association in the genome-wide association study, because of inaccuracy of in silico prediction models.
Alternative splicing resulting in abnormal protein sequences is a tightly regulated physiological process. However, genetic variants can disrupt processes involved in splicing machinery. Exonic or intronic variants in the canonical splice consensus can weaken or abolish canonical splice sites and exonic synonymous or intronic variants can create cryptic splice sites. In addition, various genetic variants can also affect enhancer or silencer elements in the gene or can alter the expression or activity of splicing regulatory proteins. Our study fuels the concept that abnormal splicing may play a larger role in pathogenicity than widely appreciated, and might even be a relatively common cause for monogenic disorders. 13 There are many examples of deep intronic mutations that are related to disease phenotypes. 13 Their distance from the exon-intron boundaries can range from a couple of hundred bps (eg, c.6937+594T>G in the breast cancer 2 [BRCA2] gene 14 ) up to thousands of bps into introns (eg, 3849+10KbC>T in the cystic fibrosis transmembrane conductance regulator [CFTR] gene 15 ). It can be hypothesized that, in resemblance to these 2 examples, yet unidentified deep intronic variants in the LDLR gene might affect splicing and thus explain some FH4 cases. We, therefore, propose to perform complete LDLR gene sequencing, including the promoter and intronic regions, in FH4 patients to elucidate the molecular basis of the FH phenotype.
High-throughput genome-wide techniques in combination with improved in silico prediction tools are crucial in determining the prevalence and clinical relevance of intronic variants. The real challenge, however, is not the detection of these variants, but the evaluation of their pathogenicity in a clinical setting. In silico prediction tools to ascertain splicing, as we have used here, are not always correct in calling splice sites. 16 As a consequence, mRNA analyses and cosegregation analyses remains necessary, which often is a costly and timely labor for diagnostic laboratories.
The current study is limited by its lack of in vitro confirmation of the pathogenicity of c.2140+103G>T, such as the effect on LDLR protein expression and LDL-C uptake. However, we observe a 100% penetrance of this variant in 2 families over 3 generations. Moreover, the intronic variant was shown to result in a premature stop codon in exon 15, probably resulting in a truncation of the LDLR protein or reduced LDLR protein synthesis. Lastly, the identification of additional unrelated heterozygous carriers of the mutation among patients with the same FH phenotype strongly suggests that this variant may result in loss of function of the LDLR protein.
In conclusion, c.2140+103G>T is a novel deep intronic mutation in LDLR that causes FH. The current finding suggests that the molecular basis of FH patients with unknown FH causing mutations can at least partly be explained by yet undiscovered (deep) intronic variants. This emphasizes the need to widen the scope from LDLR exome sequencing toward whole LDLR gene sequencing in patients with a yet unknown genetic cause of FH.
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